GEN Exclusives

More »

GEN News Highlights

More »
Sep 8, 2009

RiNA and 5 Prime Take Over Roche’s RTS Protein-Expression Portfolio

  • Roche has transferred its entire portfolio of Roche Applied Science RTS cell-free protein-expression kits to German companies RiNA and 5 Prime. RiNA will manufacture the products, and 5 Prime will be responsible for sales, support, and distribution of the RTS portfolio worldwide.

    Roche says that because of its own focus on new genomics technologies, the RTS technology is better placed with a company that is more specialized in proteomics. RiNA has been working with Roche for a number of years and was involved in the development of the RTS technology from the start.

    RiNA CEO, Leo W. Tristram, says that the RTS kits ideally complement its own product portfolio and services for cell-free biosynthesis. “Together with 5 Prime products for purifying and detecting recombinant proteins, RTS technology will form a strong basis for joint development of innovative products in this dynamic field.”

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?